MDHealthcare · Medical Care FacilitiesThe 7 Wall Street analysts covering Pediatrix Medical Group, Inc. hold a median 12-month price target of $28 — +3.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Pediatrix Medical Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Growth (57): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +3.5% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | Jefferies | Downgrade | Hold | $27 → $28 |
| 6 Aug 2026 | UBS | Maintains | Neutral | $25 → $28 |
| 6 Aug 2026 | UBS | Maintains | Neutral | — |
| 14 July 2026 | Truist Securities | Maintains | Hold | $23 → $28 |
| 14 July 2026 | Truist Securities | Maintains | Hold | — |
| 12 May 2026 | UBS | Maintains | Neutral | — |
| 13 Apr 2026 | Truist Securities | Maintains | Hold | — |
| 24 Feb 2026 | UBS | Maintains | Neutral | — |
| 20 Feb 2026 | Truist Securities | Maintains | Hold | — |
| 10 Nov 2025 | Truist Securities | Maintains | Hold | — |
| 5 Nov 2025 | UBS | Maintains | Neutral | — |
| 5 Sept 2025 | Leerink Partners | Maintains | Market Perform | — |
| 14 Aug 2025 | UBS | Maintains | Neutral | — |
| 12 May 2025 | UBS | Maintains | Neutral | — |
| 8 May 2025 | Macquarie | Maintains | Outperform | — |
| 11 Apr 2025 | Truist Securities | Maintains | Hold | — |
| 21 Feb 2025 | Truist Securities | Maintains | Hold | — |
| 21 Feb 2025 | UBS | Maintains | Neutral | — |
| 6 Jan 2025 | Truist Securities | Maintains | Hold | — |
| 16 Dec 2024 | Macquarie | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Pediatrix Medical Group, Inc. returned +68.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 50% of US stocks
Cheaper than 66% of US stocks
Cheaper than 37% of US stocks
Cheaper than 42% of US stocks
Higher than 36% of US stocks
Higher than 38% of US stocks
Higher than 30% of US stocks
Higher than 70% of US stocks
Higher than 68% of US stocks
Higher than 81% of US stocks
Higher than 85% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pediatrix Medical Group, Inc. has a market value of $2.2B and an enterprise value of $2.3B.
Revenue in the twelve months to 30 June 2026: $2.0B. The latest quarter grew 4.0% year on year.
Net income over the same four quarters: $174.8M, a 9.0% net margin.
Diluted earnings per share, trailing twelve months: $2.09.
Free cash flow in the twelve months to 30 June 2026: $228.6M.
Pediatrix Medical Group, Inc. spent $149.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 12.7×; forward P/E: 10.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Pediatrix Medical Group, Inc. employs 4,280 people — $456K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pediatrix Medical Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A Zacks Investment Research article titled “Why Pediatrix Medical Group (MD) is a Top Growth Stock for the Long-Term” highlights Zacks Style Scores as a way for investors to find top-rated stocks based on their investing style.
Why it matters — The item presents Zacks’ growth-stock framing of MD and describes the Style Scores approach behind it.
HB Wealth, an independent fee-only registered investment adviser, announced that Steven D. Podnos, MD, MBA, CFP®, Rachel Podnos O'Leary, JD, CFP®, and Lauren Podnos-Garner, CFP® have joined the firm, expanding its presence into Austin, Texas with a three-advisor team previously operating as Wealth Care LLC.
Why it matters — This is relevant to a MD watcher because it mentions a medical doctor (Steven D. Podnos, MD) joining a financial advisory firm, showing a physician transitioning into the wealth management industry.
Pediatrix Medical Group reported 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, with growth supported by stronger reimbursement and acquisitions.
Why it matters — This shows MD is able to grow revenue through reimbursement gains and acquisitions even as patient volumes decline.
Zacks Investment Research highlights Pediatrix Medical Group (MD) as a top momentum stock for the long term, citing its Zacks Style Scores as a way for investors to identify top-rated stocks based on investing style.
Why it matters — The positive recognition from a research firm may bolster investor confidence in Pediatrix Medical Group's stock performance over the long term.
Pediatrix Medical Group reported earnings 30 days ago, and its stock has risen 3.4% since that earnings release. The news item examines whether the stock can continue its current trajectory.
Why it matters — A Pediatrix watcher would care because the report assesses the stock's performance since the last earnings announcement and signals potential momentum for the company.
The 7 Wall Street analysts covering Pediatrix Medical Group, Inc. have a median 12-month price target of $28, with estimates ranging from $21 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Pediatrix Medical Group, Inc., 1 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pediatrix Medical Group, Inc. 99 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Pediatrix Medical Group, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +3.5% from the last close, and Ticker Nerd's factor model ranks Pediatrix Medical Group, Inc. 99 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pediatrix Medical Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $28 over the next 12 months.
Pediatrix Medical Group, Inc. returned +68.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Pediatrix Medical Group Inc. is a physician services company focused on newborn, maternal-fetal, and pediatric subspecialty care.
The most recent item we track (Zacks Investment Research, 9 Oct 2026): "Why Pediatrix Medical Group (MD) is a Top Growth Stock for the Long-Term". A Zacks Investment Research article titled “Why Pediatrix Medical Group (MD) is a Top Growth Stock for the Long-Term” highlights Zacks Style Scores as a way for investors to find top-rated stocks based on their investing style.
Pediatrix Medical Group Inc. is a physician services company focused on newborn, maternal-fetal, and pediatric subspecialty care. It provides hospital-based and office-based clinical services for premature and medically complex infants, expectant mothers, and children requiring specialized treatment. The company’s care network includes neonatologists, maternal-fetal medicine specialists, pediatric subspecialists, nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. Pediatrix Medical Group also supports hospitals and health systems with clinical staffing and related physician-led service lines across neonatal intensive care, women’s health, pediatric cardiology, pediatric critical care, pediatric emergency medicine, and anesthesia care. Headquartered in Sunrise, Florida, Pediatrix Medical Group plays an important role in delivering specialized care in high-acuity settings where coordinated expertise and continuity of treatment are essential.
CEO Mr. Mark S. Ordan · 4,280 employees · United States · https://www.pediatrix.com
